A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Completed · Phase 2 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive

In brief

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Key facts

Study ID

NCT00808288

Run by

Pfizer

People needed

405

Starts

2010-03-01

Expected to finish

2010-12-01

Last updated by the study team

2019-02-06

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Post-bronchodilator FEV1/FVC ratio <0.7 and a post-bronchodilator FEV1 of 50-80%.
• Diagnosis of moderate COPD for a minimum of 6 months.
• Stable disease for at least 1 month prior to screening

You may not qualify if…

• More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
• History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.

Where it is running

• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Spring Valley, California, United States
• Pfizer Investigational Site — Wheat Ridge, Colorado, United States
• Pfizer Investigational Site — Daytona Beach, Florida, United States
• Pfizer Investigational Site — Ormond Beach, Florida, United States
• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — Trinity, Florida, United States
• Pfizer Investigational Site — Austell, Georgia, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Overland Park, Kansas, United States
• Pfizer Investigational Site — Fridley, Minnesota, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — Rochester, Minnesota, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Charlotte, North Carolina, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Lincoln, Rhode Island, United States
• Pfizer Investigational Site — Pawtucket, Rhode Island, United States
• Pfizer Investigational Site — Charleston, South Carolina, United States
• Pfizer Investigational Site — Fairhope, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.